Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).
1 finding from 1 review
Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).
1 finding from 1 review
Physical fitness · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Fatigue · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Health‐related quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer site‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Depression · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cognitive function · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Adverse events: lymphoedema · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Survival ‐ overall · Women (70 years plus) with operable primary breast cancer
Surgery showed no clear difference in survival ‐ overall compared with primary endocrine therapy (low certainty).
1 finding from 1 review
Intervention not reported
Febrile neutropenia Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to lower febrile neutropenia Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Injection‐site reaction Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to higher injection‐site reaction Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Early mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower early mortality Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Infection‐related mortality Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in infection‐related mortality Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Severe neutropenia (WHO grade IV) Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in severe neutropenia (WHO grade IV) Rates of patients (moderate certainty).
1 finding from 1 review
Intervention not reported
Infections Rates of patients · breast cancer patients undergoing chemotherapy
The intervention showed no clear difference in infections Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Hospitalization Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower hospitalization Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Antibiotics (i.v.) Rates of patients · breast cancer patients undergoing chemotherapy
The intervention may leads to lower antibiotics (i.v.) Rates of patients (low certainty).
1 finding from 1 review
Intervention not reported
Bone pain Rates of patients · breast cancer patients undergoing chemotherapy
The intervention probably leads to higher bone pain Rates of patients (moderate certainty).
1 finding from 1 review